We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 150.00 | 140.00 | 160.00 | 150.00 | 150.00 | 150.00 | 4,213 | 07:44:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.59 | 103.18M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/1/2019 13:00 | stock going up looks like some good news on the way... | bioking | |
30/1/2019 11:58 | Only 31 million shares outstanding and almost 40% of these shares held by the 10 largest shareholder alone which didnt sell even after 90% drop .Stock coming from over 800p now trading at 55p .stock will rally if the Japan phase 3 results are positive which could come anytime now . Marko Salmi 3 093 439 Aviva Investors Global Services Ltd. 1 518 814 Hargreave Hale Ltd. 1 475 875 Polar Capital LLP 1 452 381 Timo Kalevi Syrjälä 1 390 830 Juho Markku Jalkanen, MD 1 082 570 Rhenman & Partners Asset Management AB 759 265 Keskinäinen Eläkevakuutusyh Hargreave Hale Ltd. (Venture Capital) 167 154 Amati Global Investors Ltd. (Venture Capital) 122 993 | bioking | |
30/1/2019 11:01 | Faron Pharma (FARN) = Market cap 17 million / YODA Results & Final Phase 3 results from Japan IMMINENT / Traumakine as orhpan Drug has over $500 million in sales potential / NO approved Drug to date for the treatment of ARDS = 1000% UPSIDE Potential easily The YODA study will now examine concomitant administration of prednisolone and Traumakine in order to confirm, in vivo, the observed interference of corticosteroids on IFN-beta bioactivity in the INTEREST study and ex vivo lung samples. These YODA results are expected during Q1 2019. The company continues to await top-line data from the Phase III ARDS trial with Japanese partner Maruishi (JapicCTI-163320) to help determine next steps for Traumakine's development. These data, originally expected before the end of year, are now anticipated by Faron in early 2019. Faron Pharma confident Traumakine could be ‘very effective’ for ARDS subgroup [...] Faron Pharma (LON:FARN) CEO Markku Jalkanen tells Proactive London’s Andrew Scott he's confident their Traumakine drug has the potential to treat around a third of acute respiratory distress syndrome (ARDS) patients in Europe and North America ARDS is a life-threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu. Following on from a phase III trial of Traumakine earlier this year scientists have discovered that patients with a particular type of genetic mutation - called a C/T mutation - were almost six times more likely to survive than those who were also taking the drug but didn’t have the mutation Faron will now liaise with European and US regulators to figure out the next best step for the drug. | bioking | |
29/1/2019 02:55 | There's only ONE share to own right now.........which one's that? I hear you cry.... HEMOGENYX (HEMO) of course!!!! dyor | badger60 | |
03/1/2019 12:49 | temporary setback. wait for the bounce before diving in | jobber1 | |
03/1/2019 12:39 | miahkaysor7 Dec '18 - 14:21 - 1097 of 1099 0 4 0 £1 by Christmas? 2020? | alamaison5 | |
28/12/2018 17:48 | absence of trolls here. Maybe that is going to work better next year on this stock | jobber1 | |
28/12/2018 12:06 | Looks like market undecided here. Hardly any buys maybe it’s funding | zen12 | |
07/12/2018 14:21 | £1 by Christmas? | miahkaysor | |
07/12/2018 10:17 | Way to cheap | troajan1 | |
05/12/2018 17:53 | https://www.proactiv | dan1nat1 | |
05/12/2018 11:13 | Sorry that was TCG | joecase | |
05/12/2018 11:09 | RNS non ex director buy dyor | joecase | |
05/12/2018 11:03 | L2 4 orders @ 85p. 31%blue | joecase | |
05/12/2018 10:47 | We should be back to 120p as a minimum on this news IMHO... (i.e. where we were prior to the last big drop)….my expectation would be that there is still a 50% upside from here in the next few days ....BWDIK, DYOR, not for WIDOWS/ORPHANS etc. etc... GLA DL | davidlloyd | |
05/12/2018 10:00 | People die of ARDS in a few minutes!!!!! | eezymunny | |
05/12/2018 09:53 | Ocr tests take a few minutes nowadays | letmepass | |
05/12/2018 09:52 | CMO buys 20000 @ 82.90 in November 18. Dyor | joecase | |
05/12/2018 09:45 | "The identification of these C/T patients is very easy with PCR-based analysis of a patient's DNA sample" As I say you have to do a PCR test to see if the FARN treatment is suitable. Is the patient not dead before the results come back? | eezymunny | |
05/12/2018 09:38 | Took a few :) | texas boy | |
05/12/2018 08:43 | Seriously u must of lost a fortune here on your short | rakepat37 | |
05/12/2018 08:42 | You do not know this shares no money you loon. 120p close today. | mr motivator | |
05/12/2018 08:41 | So some poor sod is gasping for breath in intensive care and the doctors have to send away for a DNA test to see if FARN's offering is suitable? Giraffe giraffe! | eezymunny |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions